Together, these data show that the expansion of CD8 CAR-T cells in IL-2 attenuated mitochondrial respiration in these cells compromising their ability to kill cancer cells in vivo, and that loss of MCJ in CAR-T cells enhances mitochondrial metabolism and overall metabolic fitness, resulting in an improved anti-tumor efficacy in vivo. This evidence concerns the gene CD8A and neoplasm.